Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348989 | 0.84 | HTR1A (0.53) | SLC6A4HTR1A | |
| SCHEMBL1206920 | 0.83 | HTR1A (0.64) | SLC6A4HTR1ASIGMAR1SLC6A2SLC6A3 | |
| SCHEMBL10021746 | 0.79 | HTR1A (0.62) | SLC6A4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL7289000 | 0.78 | SLC6A2 (0.57) | SLC6A4SIGMAR1SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5750545 | 0.77 | LTA4H (0.49) | SLC6A4HTR1ASIGMAR1SLC6A2SLC6A3 | |
| SCHEMBL351932 | 0.77 | HTR1A (0.69) | HTR1A | |
| SCHEMBL10021759 | 0.77 | HTR1A (0.63) | SLC6A4HTR1ASIGMAR1SLC6A2SLC6A3 | |
| SCHEMBL10982483 | 0.77 | SIGMAR1 (0.51) | SLC6A4SIGMAR1SLC6A2SLC6A3KCNH2 | |
| SCHEMBL8238268 | 0.76 | SLC6A2 (0.40) | SLC6A4HTR1ASIGMAR1SLC6A2SLC6A3 | |
| SCHEMBL10021749 | 0.76 | HTR1A (0.48) | SLC6A4HTR1ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7893261-B2 | bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity | BAYLOR UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | BAYLOR UNIVERSITY | 2008-06-05 | — | — | US | disclosed |
| EP-1732610-A2 | TARGETED SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005094896-A2 | TARGETED SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | HTR2A, HTR2C, HTR1A | SLC6A4 8/4885HTR1A 3/4885SIGMAR1 53/4885 |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | HTR2A, HTR2C, HTR1A | SLC6A4 8/4885HTR1A 3/4885SIGMAR1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.